Secukinumab and acitretin as a combination therapy for three clinical forms of severe psoriasis in multi‐drug refractory patients: A case series of high efficacy and safety profile

2021 ◽  
Author(s):  
Algün Polat Ekinci ◽  
Kübra Nursel Bölük ◽  
Goncagül Babuna Kobaner
Keyword(s):  
Combination Therapy ◽  
Safety Profile ◽  
Case Series ◽  
Severe Psoriasis ◽  
Efficacy And Safety ◽  
High Efficacy ◽  
Clinical Forms

scholarly journals Outcomes of combination therapy for stage IIA–IIIB cervical cancer

2019 ◽  
Vol 14 (4) ◽  
pp. 50-55
Author(s):  
D. K. Reyes Santiago ◽  
A. S. Khadzhimba ◽  
I. V. Sobolev ◽  
A. A. Ilyin ◽  
S. Ya. Maksimov
Keyword(s):  
Cervical Cancer ◽  
Combination Therapy ◽  
Standard Treatment ◽  
Efficacy And Safety ◽  
High Efficacy ◽  
Relapse Free Survival ◽  
Free Survival ◽  
Group 2 ◽  
Study Participants ◽  
Group 1

Objective: to analyze treatment outcomes in patients with stage IIA–IIIB cervical cancer.Materials and methods. The study included 278 women with stage IIA–IIIB cervical cancer. Study participants were divided into 2 groups. Group 1 comprised 165 patients who received chemoradiotherapy + surgery (radical hysterectomy). Patients in group 2 received standard radiotherapy.Results. Patients receiving combination therapy demonstrated better overall and relapse-free survival compared to those receiving standard treatment.Conclusion. Both publications of other authors and our own results suggest high efficacy and safety of combination therapy for stage IIA–IIIB cervical cancer.

scholarly journals Efficacy and Safety Profile of Ixazomib Based Regimens in Relapsed/Refractory Multiple Myeloma: A Meta-Analysis of Clinical Trials

Blood ◽  
2020 ◽  
Vol 136 (Supplement 1) ◽  
pp. 20-21
Author(s):  
Ahmad Iftikhar ◽  
Muhammad Ashar Ali ◽  
Anum Javaid ◽  
Muhammad Abu Zar ◽  
Atif Sohail ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Clinical Trials ◽  
Safety Profile ◽  
Randomized Clinical Trials ◽  
Meta Analysis ◽  
Case Series ◽  
Pooled Analysis ◽  
Phase Iii ◽  
Efficacy And Safety ◽  
Grade 3

Background: Multiple myeloma (MM) is an incurable disease, and clinical trials with newer agents have shown improved patient outcomes. There is a need for effective and tolerable treatment for patients with relapsed/refractory MM (RRMM). Proteasome inhibitors (bortezomib, carfilzomib, ixazomib) remain an integral part of regimens used in RRMM or newly diagnosed (ND) MM. This meta-analysis aims to assess the efficacy and safety of ixazomib (Ixa) based regimens in RRMM. Methods: A comprehensive literature search was performed on PubMed, Cochrane, Embase, Web of Science, and clinicaltrials.gov. We used MeSH and Emtree terms, "ixazomib" AND "multiple myeloma" from the inception of literature till 06/01/2020. We screened 1529 articles and included 3 randomized clinical trials (RCT, N=907) and 8 non-randomized clinical trials (NRCT, N=321). We excluded case reports, case series, review articles, meta-analysis, observational studies, and clinical trials that didn't provide data about the efficacy and safety of Ixa in RRMM. We used the R programming language (version 4.0.2) to conduct a meta-analysis. Results: In 11 clinical trials (N=1228), the age range of patients was 30-91 years. In Phase III RCTs (N=837) comparing Ixa + Lenalidomide (Len) + dexamethasone (Dex) vs. placebo + Len + Dex, risk ratio of overall response rate (ORR), complete response (CR), and very good partial response (VGPR) were 1.14 (95% CI=1.05-1.24, I2=80%), 1.87 (95% CI=1.17-2.99, I2=0), and 1.15 (95% CI=0.95-1.40, I2=0), respectively in favor of Ixa + Len + Dex. (Fig 1-3) Grade 3 or higher treatment-related adverse events (TRAEs) thrombocytopenia, diarrhea, and rash were reported in 20%, 5.7% and 6.4% of the patients in the Ixa group vs. 10%, 2.1%, and 2.8% in the placebo group, respectively. In a Phase II RCT by Kumar et al (N=70) comparing the Ixa dosage, 4 mg Ixa + Dex yielded an ORR of 31%, CR 2.8%, and VGPR 17.1%, while 5.5 mg Ixa yielded improved ORR of 54%, CR 2.8%, and VGPR 25.7%. In a NRCT by Costello et al. (N=6), Ixa + daratumumab (Dara) + Pom + Dex yielded 100% ORR, CR 5% (95% CI=0.17-0.83), and VGPR 50% (95% CI=0.17-0.83). ≥Grade 3 TRAEs were hypertension (16%), and hematological (33%). Among 417 patients from two RCT in single arm who received Ixa + Len + Dex, pooled ORR was 70% (95% CI=0.53-0.82, I2=84%), pooled CR 11% (95% CI=0.8-0.14, I2=0), and pooled VGPR was 29% (95% CI=0.18-0.43, I2=66%). In a NRCT by Dhakal et al. (N=19), Ixa + bendamustine + Dex yielded an ORR 58% (95% CI=0.36-0.77), CR 0, and VGPR 11% (95% CI =0.03-0.34). ≥Grade 3 TRAEs were neutropenia 31%, thrombocytopenia 52%, and diarrhea 10%. In 2 NRCT (N=106), Ixa + cyclophosphamide (Cyc) + Dex yielded a pooled ORR 52% (95% CI=0.42-0.61, I2=0), CR 4% (95% CI=0.01-0.10, I2=0), and VGPR 17% (95% CI=0.11-0.25, I2=0). ≥Grade 3 TRAEs were thrombocytopenia (15%), and upper abdominal pain (4%). In a NRCT by Ludwig et al. (N=90), Ixa + thalidomide (Thal) + Dex yielded an ORR 51% (95% CI=0.41-0.61), CR 9% (95% CI=0.5-0.17), and VGPR 14% (95% CI=0.09-0.23). ≥Grade 3 TRAEs were anemia (17.8%), and infections (16.1%). In a NRCT by Krishnan et al. (N=31), Ixa + Pomalidomide (Pom) + Dex yielded an ORR 48% (95% CI=0.32-0.65) and VGPR 16% (95% CI=0.07-0.33). (Fig 4-6) ≥Grade 3 TRAEs were neutropenia (10%), and lymphopenia (35%). In 2 NRCT by Kumar et al. (N=70) of two drugs combination, Ixa + Dex yielded a pooled ORR 43% (95% CI=0.28-0.59, I2=47%), pooled CR 1% (95% CI=0-0.09, I2=0), and pooled VGPR 24% (95% CI=0.16-0.36, I2=0). ≥Grade 3 TRAEs were hematological (28%), and non-hematological (22.8%). In 2 NRCT of Ixa monotherapy (N=69), pooled ORR was 17% (95% CI=0.10-0.28, I2=0), and pooled CR 6% (95% CI=0.2-0.22, I2=0). (Fig 4-6) ≥Grade 3 TRAEs were anemia (11%), thrombocytopenia (5.4%), and neutropenia (2.7%). Conclusion: Our study provides useful insight into relative efficacy of various Ixa regimens for the treatment of RRMM. The pooled analysis of RCT showed that the combination of Ixa + Len + Dex yielded better response as compared to placebo. In the pooled analysis of outcomes in single arm NRCT, Ixa + Dara + Pom + Dex and Ixa + Len + Dex showed better efficacy outcomes as compared to Ixa + Dex in combination with Thal, Cyc, or Bendamustin. Three drugs Ixa combination regimens had better efficacy as compared to two drugs combination of Ixa + Dex and Ixa monotherapy. Ixa was well tolerated with acceptable safety profile. Additional multicenter, double-blind clinical trials are needed to confirm these results. Disclosures Anwer: Incyte, Seattle Genetics, Acetylon Pharmaceuticals, AbbVie Pharma, Astellas Pharma, Celegene, Millennium Pharmaceuticals.: Honoraria, Research Funding, Speakers Bureau.

scholarly journals Fenspiride use in acute respiratory infections in children

2019 ◽  
pp. 120-123
Author(s):  
N. G. Kolosova ◽  
M. D. Shakhnazarova
Keyword(s):  
Safety Profile ◽  
Respiratory Diseases ◽  
Respiratory Infections ◽  
Economic Problem ◽  
Acute Respiratory Infections ◽  
Efficacy And Safety ◽  
High Efficacy ◽  
Acute Respiratory Diseases ◽  
Anti Inflammatory

Acute respiratory infections are the most common pathology in childhood, representing not only a medical but also a socio-economic problem. Numerous studies on the use of anti-inflammatory therapy in ARI have shown high efficacy and safety profile of fenspiride. The combination of anti-inflammatory, antiallergic, and antispasmodic properties ensures the success of fenspiride in the treatment of acute respiratory diseases in children. Fenspiride reduces symptoms of ARI, accelerates recovery, reduces the need for additional prescription of other drugs.

scholarly journals Aprotinin ‐ a new multi-target drug candidate or "magic shotgun" for the therapy of COVID‐19

2020 ◽  
Author(s):  
Andrey Ivashchenko ◽  
Andrey Svistunov ◽  
Tatiana Khorobryh ◽  
Vladimir Loginov ◽  
Ruben Karapetian ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Prospective Study ◽  
Hospitalized Patients ◽  
Drug Candidate ◽  
Efficacy And Safety ◽  
High Efficacy ◽  
Target Drug ◽  
A Prospective Study

Aprotinin showed high efficacy and safety in a prospective study of combination therapy for hospitalized patients with moderate to severe COVID-19 pneumonia.

scholarly journals Experience of lordestin (desloratadine) use in patients with seasonal allergic rhinitis

2012 ◽  
Vol 9 (1) ◽  
pp. 79-83
Author(s):  
N I Ilyina ◽  
K S Pavlova
Keyword(s):  
Allergic Rhinitis ◽  
Combination Therapy ◽  
Safety Profile ◽  
Seasonal Allergic Rhinitis ◽  
Hay Fever ◽  
Efficacy And Safety ◽  
Ocular Symptoms ◽  
Good Safety Profile ◽  
Highly Effective

The article presents the results of the study of the Lordestin's (desloratadine) efficacy and safety in patients with seasonal allergic rhinitis. The results showed that Lordestin is highly effective in reducing of the severity of nasal and ocular symptoms in patients with hay fever, has a good safety profile and may be recommended as a monotherapy or as a component of combination therapy in patients with allergic rhinitis.

Sign in / Sign up

Export Citation Format

Share Document